Newly released research shows that those with chronic back pain may want to seriously considering using CBD cream to treat their symptoms.
A study published in the Journal of Opioid Management, and epublished by the National Institute of Health, has found that hemp-derived cannabidiol (CBD) cream is directly associated with pain-relieving effects in study participants who have chronic back pain.
For the case report researchers used commercially sold and transdermal formulation of CBD – specifically they used Baskin Essentials Body Wellness Cream – in two individuals. Both individuals with chronic back pain reported experiencing “significant symptom and pain relief” just minutes or hours after using the CBD cream. The study found that these pain-reliving effects lasted between eight and ten hours.
The study concludes by stating that “This case series suggests that CBD may have antinociceptive and anti-inflammatory effects on opioid-naive patients with neuropathic and radicular pain”, noting that “we believe further investigation is warranted to see if these products have a role in the treatment of acute and chronic pain.”
The full abstract of the study can be found below:
Objective: Two patient case reports are presented describing the use of cannabidiol (CBD) for the symptomatic relief of a lumbar compression fracture and in the mitigation of thoracic discomfort and dysesthesia secondary to a surgically resected meningioma.
Discussion: CBD appears to have antisnociceptive and anti-inflammatory effects on opioid-naive patients with neuro-pathic and radicular pain. Of note, the patients in this case series used the same CBD cream: Baskin Essentials Body Wellness Cream (400 mg CBD per two oz.) Conclusion: Hemp-derived CBD in a transdermal cream provided significant symptom and pain relief for the patients described in this case series. Based on these results, we believe further investigation is warranted to see if CBD-containing products should have a more prominent role in the treatment of acute and chronic pain.
The study’s affiliations can be found below:
Department of Anesthesiology and Pain Medicine, Portsmouth Anesthesia Associates, Ports-mouth, Virginia.
Department of Chemistry, University of California, San Diego, California.
Department of Chemistry, University of California, Berkeley, California.
Department of Anesthesiology, Louisiana State University Health Sciences Center-Shreveport, Shreve-port, Louisiana.
Department of Anesthesiology and Pharmacology, Louisiana State University School of Medicine, New Or-leans, Louisiana.
According to a study published earlier this year in the European Journal of Pain, delivering a precise doses of THC via a specialized inhaler is associated with pain mitigation in patients with chronic pain. The study is titled Pharmacokinetics, efficacy, and safety of a novel selective-dose cannabis inhaler in patients with chronic pain: A randomized, double-blinded, placebo-controlled trial.